• Reduksin (Sibutramin) 15mg x 60tab


Reduxin is indicated for weight loss in the following conditions: 

Alimentary obesity with a body mass index (BMI) of 30 kg / m2 or more;

alimentary obesity with BMI 27 kg / m2 and more in combination with type 2 diabetes and dyslipidemia.


Composition 

Sibutramine + Cellulose microcrystalline 

Form release

Gelatin capsules are solid


Pharmacological action

Enterosorbent, anorexigenic


Method of administration and dose

Inside, once a day, in the morning, without chewing and drinking enough amount of liquid (a glass of water). The drug can be taken either on an empty stomach or in combination with food intake.

The dose is set individually, depending on tolerability and clinical efficacy. The recommended starting dose is 10 mg, with a tolerance of 5 mg. If within 4 weeks of the onset of treatment, body weight loss is less than 2 kg, then the dose is increased to 15 mg / day.

Treatment with Redoxin should last for more than 3 months in patients who do not respond well to therapy, i.e. which for 3 months of treatment can not achieve a reduction in body weight by 5% from the original indicator. Treatment should not be continued if in the course of further therapy after the achieved reduction in body weight, the body weight of the patient increases by 3 kg or more.

The duration of treatment should not exceed 1 year, since there are no data on efficacy and safety regarding a longer period of sibutramine administration.


Treatment with Reduxin must be done in conjunction with a diet and physical exercises under the control of a physician experienced in the treatment of obesity


Contraindications

established hypersensitivity to sibutramine or other components of the drug;

the presence of organic causes of obesity (eg hypothyroidism);

serious malnutrition (nerve anorexia or bulimia nervosa);

mental illness;

syndrome of Gilles de la Tourette (generalized tick);


simultaneous administration of MAO inhibitors (eg, phentermine, phenfluramine, dexfenfluramine, ethylamphetamine, ephedrine) or their use within 2 weeks prior to the administration of Reduxin® and 2 weeks after the end of its administration; other drugs acting on the CNS that inhibit serotonin reuptake (eg antidepressants), neuroleptics, sleeping pills containing tryptophan, as well as other centrally acting drugs for weight loss or for the treatment of mental disorders;

Cardiovascular diseases (in history and presently): ischemic heart disease (myocardial infarction (MI), angina pectoris); chronic heart failure in the stage of decompensation, occlusive diseases of the peripheral arteries, tachycardia, arrhythmia, cerebrovascular diseases (stroke, transient disorders of the cerebral circulation);

uncontrolled arterial hypertension (BP above 145/90 mm Hg - see also "Special instructions");


thyrotoxicosis;

severe impairment of liver and / or kidney function;

benign prostatic hyperplasia;

pheochromocytoma;

closed-angle glaucoma;

established pharmacological, narcotic or alcohol dependence;

pregnancy;

breastfeeding period;


age 18 and over 65 years old.


Special instructions

Radoxin should only be used in cases where all non-pharmacological measures to reduce body weight are ineffective - if weight loss for 3 months was less than 5 kg.

Treatment with Redoxin should be carried out within the framework of integrated therapy to reduce body weight under the control of a physician with practical experience in the treatment of obesity.


Integrated therapy involves both a change in diet and lifestyle as well as an increase in physical activity.

An important component of therapy is the creation of prerequisites for a lasting change in eating habits and lifestyles that are necessary to maintain the achieved reduction in body weight and after the abolition of drug therapy. Patients need to be treated with the Redox drug therapy in order to ensure that the body weight loss achieved is maintained after treatment has been completed.

Patients should be aware that failure to comply with these requirements will result in a re-increase in body weight and repeated appeals to the attending physician.

Patients taking Reduxin® need to measure blood pressure and heart rate. In the first 3 months of treatment, these parameters should be monitored every 2 weeks and then monthly. If two consecutive visits show a heart rate increase at rest ≥ 10 ud / min or CAD / DAD ≥10 mm Hg. Art., it is necessary to stop the treatment. Patients with arterial hypertension, who have a blood pressure higher than 145/90 mm Hg on antihypertensive therapy. This control should be carried out especially carefully and, if necessary, at shorter intervals. Patients whose blood pressure was twice as high as 145/90 mm Hg twice during re-measurement. Treatment with Reduxin® should be discontinued.


The interval between the intake of MAO inhibitors (including furazolidone, procarbazine, selegilin) and the Reduxindolgin preparation is at least 2 weeks.

Although there is no link between the administration of Reduxin® and the development of primary pulmonary hypertension, however, given the well-known risk for this group, regular medical attention requires special attention to be given to symptoms such as progressive dyspnea (respiratory failure), chest pain and edema legs

When a dose of Reduxin® is not given, the doses of the drug should not be taken in the next dose; it is recommended that the drug be continued according to the prescribed procedure.


When co-administering sibutramine and other serotonin reuptake inhibitors, there is an increased risk of bleeding. Sibutramine should be used with caution in patients predisposed to bleeding, as well as receiving medications that affect haemostasis or platelet function.

Although there is no clinical evidence of addiction to sibutramine, it should be determined whether there was a history of drug dependence in the history of the patient and to pay attention to possible signs of drug abuse.

Influence on the ability to drive vehicles and mechanisms. Reception of the drug Redux can limit the ability to drive motor vehicles and control mechanisms. During the use of Reduxin ®, caution should be exercised when driving vehicles and occupying other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.


Notes

Since there is so far not enough research on the safety of the effects of sibutramine on the fetus, this drug is contraindicated during pregnancy.

Women of childbearing age should use contraceptives while taking Radoxindol.

It is contraindicated to take Reduxin the time of breastfeeding.

Write a review

Note: HTML is not translated!
    Bad           Good

Reduksin (Sibutramin) 15mg x 60tab

  • Product Code: Sibutramin
  • Availability: In Stock
  • 140.00€